Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Genome-Scale CRISPRi Atlas Maps Gene Function Across Human iPSCs

Published

on

A new genome-scale atlas is offering an unprecedented look at how individual genes shape the transcriptional landscape of human induced pluripotent stem cells (iPSCs). Published in Nature Biotechnology, the resource catalogs the effects of perturbing 11,692 expressed genes across more than 2.5 million single cells, creating a reference framework for understanding how pluripotent identity is maintained and regulated.

The study is titled, “A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.”

Human iPSCs can differentiate into virtually any cell type, yet the functions of most genes within this state remain poorly understood. Prashant Mali, PhD, senior author and professor of bioengineering at UC San Diego, said the team set out to fill that gap by systematically switching off genes one by one using CRISPR interference (CRISPRi) and measuring the resulting transcriptome-wide changes. “The result is a kind of reference atlas; it’s a way to look up what perturbing almost any gene does to a stem cell’s behavior, measured here as the impact on its whole transcriptome,” Mali said.

The dataset captures how gene perturbations cluster into shared molecular signatures, revealing functional relationships among protein complexes, metabolic pathways, and self-renewal genes. By correlating transcriptional phenotypes across thousands of perturbations, the researchers reconstructed a map of the pluripotent state that recapitulates known regulatory modules while surfacing previously unrecognized ones.

Exploring the atlas led the team to identify new regulators of stem cell biology. They uncovered ZBTB41 as a metabolic factor and RNF7 as a contributor to pluripotency regulation, validating both through metabolic tracing, immunofluorescence, and protein–protein interaction assays. The resource also enabled a genome-scale screen of A‑to‑I RNA editing modulators, revealing DBR1 as a potent regulator of adenosine-to-inosine conversion.

Co-first author Yesh Doctor, a bioengineering PhD student in Mali’s lab, described the atlas as a “hypothesis engine” for stem cell researchers. Instead of running thousands of perturbation experiments, scientists can now query the open-access map to identify candidate genes involved in differentiation, metabolism, or disease-relevant pathways. “Scientists can use it to look up the functions of genes and build hypotheses on them instead of having to run the experiments themselves,” Doctor said.

Beyond basic biology, the team sees the atlas as a foundation for computational modeling. The scale and consistency of the dataset make it well suited for training AI systems aimed at predicting genotype–phenotype relationships. “These comprehensive, genome-scale screens enable generation of reference maps that are not just invaluable for basic science discovery, but also an important resource for powering future computational and AI tools for genotype-phenotype prediction,” Mali said.

The open-access atlas is available here, providing a new reference point for understanding how genes shape human stem cell identity and offering a tool for virtual disease modeling and target discovery.

The post Genome-Scale CRISPRi Atlas Maps Gene Function Across Human iPSCs appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read